Edition:
United States

Proteostasis Therapeutics Inc (PTI.OQ)

PTI.OQ on NASDAQ Stock Exchange Global Market

2.73USD
20 Jul 2018
Change (% chg)

-- (--)
Prev Close
$2.73
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
335,784
52-wk High
$8.61
52-wk Low
$1.41

Chart for

About

Proteostasis Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant... (more)

Overall

Beta: --
Market Cap(Mil.): $100.31
Shares Outstanding(Mil.): 36.08
Dividend: --
Yield (%): --

Financials

  PTI.OQ Industry Sector
P/E (TTM): -- 217.69 33.34
EPS (TTM): -2.06 -- --
ROI: -78.23 -3.65 13.18
ROE: -87.03 -5.62 15.09

BRIEF-Proteostasis Therapeutics Says CFO Helen Boudreau Provided Notice Of Resignation

* PROTEOSTASIS THERAPEUTICS SAYS ON MAY 2, CFO AND TREASURER, HELEN BOUDREAU, PROVIDED NOTICE OF RESIGNATION TO PURSUE ANOTHER PROFESSIONAL OPPORTUNITY

May 07 2018

BRIEF-Proteostasis Therapeutics Files For Mixed Shelf Of Up To $100 Mln

* PROTEOSTASIS THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILING Source text: [https://bit.ly/2H14NPj] Further company coverage:

Apr 06 2018

BRIEF-Proteostasis Receives FDA Fast Track Designation For Triple Combination Program In Patients With Cystic Fibrosis

* PROTEOSTASIS THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR TRIPLE COMBINATION PROGRAM IN PATIENTS WITH CYSTIC FIBROSIS

Apr 04 2018

BRIEF-Proteostasis Announces Proposed Public Offering Of Common Stock

* PROTEOSTASIS THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Mar 19 2018

BRIEF-Proteostasis Therapeutics Expects Cash, Cash Equivalents,Short-Term Investments To Be Enough To Fund Its Operating Expenses

* PROTEOSTASIS THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

Mar 14 2018

BRIEF-Proteostasis Therapeutics Sees Cash, Cash Equivalents Balance As Of Dec 31, Sufficient To Fund Operations Into Early 2019​

* PROTEOSTASIS THERAPEUTICS INC - CO ESTIMATES CASH, CASH EQUIVALENTS BALANCE AS OF DEC 31, 2017, SUFFICIENT TO FUND OPERATIONS INTO EARLY 2019​ Source text: (http://bit.ly/2FWFOfk) Further company coverage:

Mar 14 2018

Earnings vs. Estimates